论文部分内容阅读
近日,发表的一项系统性综述显示,对于低剂量吸入用激素(ICS)无法控制的青少年儿童哮喘患者,长效β2受体激动剂(LABA)与ICS联用在降低哮喘急性发作风险上并不优于双倍剂量ICS单用效果。
A systematic review published recently showed that long-acting β2-agonist (LABA) in combination with ICS may reduce the risk of an acute exacerbation of asthma in asthmatic children and adolescents with uncontrollable low-dose inhaled hormones (ICS) Not better than double dose ICS single effect.